ArticleJTCVS open2026
Impact of hypoplastic left heart syndrome anatomic subtype on mortality, ventricular function, and atrioventricular valve function in the current era.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aortic atresia/mitral stenosis (AA/MS) subtype in hypoplastic left heart syndrome (HLHS) has been associated with poor single-ventricle palliation outcomes. We evaluated whether HLHS anatomic subtype influences transplant and Fontan-takedown-free survival and right ventricular (RV) and tricuspid valve (TV) function in the current era. Methods: Retrospective chart review was done for 219 consecutive neonates with HLHS who received a Norwood at our center (2006-2023). Primary outcomes were freedom from mortality/transplant/Fontan takedown post-Norwood (n = 219) and Fontan (n = 133). Moderate or greater RV dysfunction and TV failure were secondary outcomes. Log-rank and Cox regression evaluated primary outcomes; Fine-Gray model assessed secondary outcomes. Results: Post-Norwood (n = 219), we found that AA/MS was not associated with mortality/transplant/Fontan takedown (log-rank and Cox Conclusions: No association was observed between AA/MS and reduced transplant/takedown-free survival, RV function, or TV failure. Aortic stenosis was associated with increased risk of moderate or greater RV dysfunction post-Fontan. We found that preoperative RV and TV dysfunction, genetic syndrome, and extracardiac anomalies remain risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.